# Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

> **NCT01656343** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 775 (actual)

## Conditions studied

- Kidney Transplantation
- Transplantation, Kidney

## Interventions

- **DRUG:** Calcineurin inhibitors (CNI)
- **DRUG:** Belatacept

## Key facts

- **NCT ID:** NCT01656343
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-31
- **Primary completion:** 2019-08-05
- **Final completion:** 2019-08-05
- **Target enrollment:** 775 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01656343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01656343, "Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01656343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*